α-Glucosidase Inhibitor Can Effectively Inhibit the Risk of Tuberculosis in Patients with Diabetes: A Nested Case-Control Study

Figure 2

Poisson regression model. (a) Adjusted for meglitinides, biguanides, α-glucosidase inhibitor, TZDs, sex, age, urbanization level, length of hospital stay, low income, and comorbidity. (b) Adjusted for sulfonylureas, biguanides, α-glucosidase inhibitor, TZDs, sex, age, urbanization level, length of hospital stay, low income, and comorbidity. (c) Adjusted for sulfonylureas, meglitinides, α-glucosidase inhibitor, TZDs, sex, age, urbanization level, length of hospital stay, low income, and comorbidity. (d) Adjusted for sulfonylureas, meglitinides, biguanides, TZDs, sex, age, urbanization level, length of hospital stay, low income, and comorbidity. (e) Adjusted for sulfonylureas, meglitinides, biguanides, α-glucosidase inhibitor, sex, age, urbanization level, length of hospital stay, low income, and comorbidity.

(a)

(b)

(c)

(d)

(e)